10 principais pivotalbiosciences.com concorrentes

maxygen.com

Maxygen is a biotech company in the San Francisco Bay Area specializing in directed evolution. The Company's molecular breeding technology creates libraries of genetic diversity with a high degree of functional content.

pumabiotechnology.com

puma biotechnology, inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. puma in-licensed the global development and commercialization rights to pb272 (neratinib, oral), pb272 (neratinib, intravenous), and pb357 in 2011. in 2022, puma in-licensed global research and development and commercial rights to alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase a. neratinib is a potent irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, her1, her2 and her4. puma has been focused on developing the oral version of neratinib, and its most advanced drug candidates are directed at the treatment of her2-positive breast cancer. puma believes that neratinib has clinical applications in the treatment of several other cancers as well, including non-small cell lung cancer and other solid tumor types that over-express or have a mutation in her2. neratinib, oral was approved by the u.s. food and drug administration in 2017 for the extended adjuvant treatment of adult patients with early stage her2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy. puma commenced commercial sales of the drug in 2017 and it is marketed in the united states as nerlynx® tablets. in february 2020, nerlynx was also approved by the fda in combination with capecitabine for the treatment of adult patients with advanced or metastatic her2-positive breast cancer who have received two or more prior anti-her2-based regimens in the metastatic setting. nerlynx was granted marketing authorization by the european commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive her2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. commercial sales commen

polpharmabiologics.com

Polpharma Biologics is one of the most modern biotechnology companies with state-of-the-art facilities across Europe. Our customized CDMO services are available for both biosimilars and innovative molecules, including next-generation biologics.